Drug intelligence / Profile preview

LB-SAL09

Development stage: Preclinical
Lead developer: LysinBio
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous, Topical

Overview

LB-SAL09 is a recombinant endolysin-based antibacterial therapy under development by LysinBio for the treatment of Staphylococcus aureus infections, including methicillin-resistant (MRSA) and vancomycin-resistant (VRSA) strains. Derived from bacteriophages, LB-SAL09 functions as a peptidoglycan hydrolase that specifically targets and cleaves the peptidoglycan layer of the S. aureus cell wall, leading to rapid osmotic lysis and cell death. This targeted mechanism of action minimizes the risk of resistance development and spares beneficial host microbiota. LB-SAL09 is currently in the discovery stage for indications such as atopic dermatitis, pneumonia, and bacteremia.

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on LB-SAL09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LB-SAL09.

Explore the full profile